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Abstract
Background and aim ‘Mapping’ onto generic preference-
based outcome measures is increasingly being used as a
means of generating health utilities for use within health
economic evaluations. Despite publication of technical
guides for the conduct of mapping research, guidance for
the reporting of mapping studies is currently lacking. The
MApping onto Preference-based measures reporting Stan-
dards (MAPS) statement is a new checklist, which aims to
promote complete and transparent reporting of mapping
studies.
Methods In the absence of previously published reporting
checklists or reporting guidance documents, a de novo list
of reporting items was created by a working group com-
prised of six health economists and one Delphi methodol-
ogist. A two-round, modified Delphi survey with
representatives from academia, consultancy, health tech-
nology assessment agencies and the biomedical journal
editorial community was used to identify a list of essential
reporting items from this larger list.
Results From the initial de novo list of 29 candidate
items, a set of 23 essential reporting items was developed.
The items are presented numerically and categorised within
six sections, namely (1) title and abstract; (2) introduction;
(3) methods; (4) results; (5) discussion; and (6) other. The
MAPS statement is best applied in conjunction with the
accompanying MAPS explanation and elaboration
document.
Conclusions It is anticipated that the MAPS statement
will improve the clarity, transparency and completeness of
reporting of mapping studies. To facilitate dissemination
and uptake, the MAPS statement is being co-published by
seven health economics and quality of life journals, and
broader endorsement is encouraged. The MAPS working
group plans to assess the need for an update of the
reporting checklist in 5 years’ time.
Keywords Mapping  Outcome Measures  Preferences 
Reporting
Introduction
The process of ‘mapping’ onto generic preference-based
outcome measures is increasingly being used as a means of
generating health utilities for application within health
economic evaluations [1]. Mapping involves the develop-
ment and use of an algorithm (or algorithms) to predict the
primary outputs of generic preference-based outcome
measures, i.e. health utility values, using data on other
indicators or measures of health. The source predictive
measure may be a non-preference-based indicator or
measure of health outcome or, more exceptionally, a
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preference-based outcome measure that is not preferred by
the local health technology assessment agency. The algo-
rithm(s) can subsequently be applied to data from clinical
trials, observational studies or economic models containing
the source predictive measure(s) to predict health utility
values in contexts where the target generic preference-
based measure is absent. The predicted health utility values
can then be analysed using standard methods for individ-
ual-level data (e.g. within a trial-based economic evalua-
tion) or summarised for each health state within a decision-
analytic model.
Over recent years, there has been a rapid increase in
the publication of studies that use mapping techniques to
predict health utility values, and databases of published
studies in this field are beginning to emerge [2]. Some
authors [3] and agencies [4] concerned with technology
appraisals have issued technical guides for the conduct of
mapping research. However, guidance for the reporting of
mapping studies is currently lacking. In keeping with
health-related research more broadly [5], mapping studies
should be reported fully and transparently to allow readers
to assess the relative merits of the investigation [6].
Moreover, there may be significant opportunity costs
associated with regulatory and reimbursement decisions
for new technologies informed by misleading findings
from mapping studies. This has led to the development of
the MAPS (MApping onto Preference-based measures
reporting Standards) reporting statement, which we sum-
marise in this paper.
The aim of the MAPS reporting statement is to provide
recommendations, in the form of a checklist of essential
items, which authors should consider when reporting a
mapping study. It is anticipated that the checklist will
promote complete and transparent reporting by research-
ers. The focus, therefore, is on promoting the quality of
reporting of mapping studies, rather than the quality of
their conduct, although it is possible that the reporting
statement will also indirectly enhance the methodological
rigour of the research [7]. The MAPS reporting statement
is primarily targeted at researchers developing mapping
algorithms, the funders of the research, and peer
reviewers and editors involved in the manuscript review
process for mapping studies [5, 6]. In developing the
reporting statement, the term ‘mapping’ is used to cover
all approaches that predict the outputs of generic prefer-
ence-based outcome measures using data on other indi-
cators or measures of health and encompasses related
forms of nomenclature used by some researchers, such as
‘cross-walking’ or ‘transfer to utility’ [1, 8]. Similarly, the
term ‘algorithm’ is used in its broadest sense to encom-
pass statistical associations and more complex series of
operations.
The development of the MAPS statement
The development of the MAPS reporting statement was
informed by recently published guidance for health
research reporting guidelines [5] and broadly modelled
other recent reporting guideline developments [9–14]. A
working group comprised of six health economists (SP,
ORA, HD, LL, MO and AG) and one Delphi methodologist
(RF) was formed following a request from an academic
journal to develop a reporting statement for mapping
studies. One of the working group members (HD) had
previously conducted a systematic review of studies map-
ping from clinical or health-related quality of life measures
onto the EQ-5D [2]. Using the search terms from this
systematic review, as well as other relevant articles and
reports already in our possession, a broad search for
reporting guidelines for mapping studies was conducted.
This confirmed that no previous reporting guidance had
been published. The working group members therefore
developed a preliminary de novo list of 29 reporting items
and accompanying explanations. Following further review
by the working group members, this was subsequently
distilled into a list of 25 reporting items and accompanying
explanations.
Members of the working group identified 62 possible
candidates for a Delphi panel from a pool of active
researchers and stakeholders in this field. The candidates
included individuals from academic and consultancy set-
tings with considerable experience in mapping research,
representatives from health technology assessment agen-
cies that routinely appraise evidence informed by mapping
studies and biomedical journal editors. Health economists
from the MAPS working group were included in the Delphi
panel. A total of 48 of the 62 (77.4 %) individuals agreed
to participate in a Delphi survey aimed at developing a
minimum set of standard reporting requirements for map-
ping studies with an accompanying reporting checklist.
The Delphi panellists were sent a personalised link to a
Web-based survey, which had been piloted by members of
the working group. Non-responders were sent up to two
reminders after 14 and 21 days. The panellists were
anonymous to each other throughout the study, and their
identities were known only to one member of the working
group. The panellists were invited to rate the importance of
each of the 25 candidate reporting items identified by the
working group on a 9-point rating scale (1, ‘not important’,
to 9, ‘extremely important’); describe their confidence in
their ratings (‘not confident’, ‘somewhat confident’ or
‘very confident’); comment on the candidate items and
their explanations; suggest additional items for considera-
tion by the panellists in subsequent rounds; and provide
any other general comments. The candidate reporting items
276 Qual Life Res (2016) 25:275–281
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were ordered within six sections: (1) title and abstract; (2)
introduction; (3) methods; (4) results; (5) discussion; and
(6) other. The panellists also provided information about
their geographical area of work, gender, and primary and
additional work environments. The data were imported into
Stata (version 13; Stata-Corp, College Station, TX) for
analysis.
A modified version of the Research ANd Development
(RAND)/University of California Los Angeles (UCLA)
appropriateness method was used to analyse the round one
responses [15]. This involved calculating the median score,
the inter-percentile range (IPR) (30 and 70th) and the inter-
percentile range adjusted for symmetry (IPRAS) for each
item (i) being rated. The IPRAS includes a correction factor
for asymmetric ratings, and panel disagreement was judged
to be present in cases if IPRi[ IPRASi [15]. We modified
the RAND/UCLA approach by asking panellists about
‘importance’ rather than ‘appropriateness’ per se. Assess-
ment of importance followed the classic RAND/UCLA
definitions, categorised simply as whether the median rat-
ing fell between 1 and 3 (unimportant), 4 and 6 (neither
unimportant nor important), or 7 and 9 (important) [15].
The results of round one of the Delphi survey were
reviewed at a face-to-face meeting of the working group. A
total of 46 of the 48 (95.8 %) individuals who agreed to
participate completed round one of the survey. Of the 25
items, 24 were rated as important, with one item (‘Source
of Funding’) rated as neither unimportant nor important.
There was no evidence of disagreement on ratings of any
items according to the RAND/UCLA method. These find-
ings did not change when the responses of the MAPS
working group were excluded. Based on the qualitative
feedback received in round one, items describing ‘Model-
ling Approaches’ and ‘Repeated Measurements’ were
merged, as were items describing ‘Model Diagnostics’ and
‘Model Plausibility’. In addition, amendments to the
wording of several recommendations and their explana-
tions were made in the light of qualitative feedback from
the panellists.
Panellists participating in round one were invited to
participate in a second round of the Delphi survey. A
summary of revisions made following round one was
provided. This included a document in which revisions to
each of the recommendations and explanations were dis-
played in the form of track changes. Panellists participating
in round two were provided with group outputs (mean
scores and their standard deviations, median scores and
their IPRs, histograms and RAND/UCLA labels of
importance and agreement level) summarising the round
one results (and disaggregated outputs for the merged
items). They were also able to view their own round one
scores for each item (and disaggregated scores for the
merged items). Panellists participating in round two were
offered the opportunity to revise their rating of the
importance of each of the items and informed that their
rating from round one would otherwise hold. For the
merged items, new ratings were solicited. Panellists par-
ticipating in round two were also offered the opportunity to
provide any further comments on each item or any further
information that might be helpful to the group. Non-re-
sponders to the second round of the Delphi survey were
sent up to two reminders after 14 and 21 days. The ana-
lytical methods for the round two data mirrored those for
the first round.
The results of the second round of the Delphi survey
were reviewed at a face-to-face meeting of the working
group. A total of 39 of the 46 (84.8 %) panellists partici-
pating in round one completed round two of the survey. All
23 items included in the second round were rated as
important with no evidence of disagreement on ratings of
any items according to the RAND/UCLA method. Quali-
tative feedback from the panellists participating in round
two led to minor modifications to wording of a small
number of recommendations and their explanations. This
was fed back to the round two respondents who were given
a final opportunity to comment on the readability of the
final set of recommendations and explanations. Based on
these methods, a final consensus list of 23 reporting items
was developed.
The MAPS statement
The MAPS statement is a 23-item checklist of recom-
mendations (Table 1) that we consider essential for com-
plete and transparent reporting of studies that map onto
generic preference-based outcome measures. The 23
reporting items are presented numerically and categorised
within six sections, namely (1) title and abstract (2 items);
(2) introduction (2 items); (3) methods (9 items); (4) results
(6 items); (5) discussion (3 items); and (6) other (1 item).
The reporting of each item does not necessarily have to
follow the order within the MAPS statement. Rather, what
is important is that each recommendation is addressed
either in the main body of the report or in its appendices.
Several biomedical journals have endorsed the MAPS
statement. These include Applied Health Economics and
Health Policy, Health and Quality of Life Outcomes, In-
ternational Journal of Technology Assessment in Health
Care, Journal of Medical Economics, Medical Decision
Making, PharmacoEconomics and Quality of Life
Research. We encourage other journals and research
interest groups to endorse the MAPS statement and authors
to adhere to its principles.
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Table 1 Checklist of items to include when reporting a mapping study
Section/topic Item
number
Recommendation Reported on page
number/line number
Title and abstract
Title 1 Identify the report as a study mapping between outcome measures. State the
source measure(s) and generic, preference-based target measure(s) used in the
study
Abstract 2 Provide a structured abstract including, as applicable: objectives; methods,
including data sources and their key characteristics, outcome measures used and
estimation and validation strategies; results, including indicators of model
performance; conclusions; and implications of key findings
Introduction
Study rationale 3 Describe the rationale for the mapping study in the context of the broader evidence
base
Study objective 4 Specify the research question with reference to the source and target measures
used and the disease or population context of the study
Methods
Estimation sample 5 Describe how the estimation sample was identified, why it was selected, the
methods of recruitment and data collection, and its location(s) or setting(s)
External validation
sample
6 If an external validation sample was used, the rationale for selection, the methods




7 Describe the source and target measures and the methods by which they were
applied in the mapping study
Exploratory data
analysis
8 Describe the methods used to assess the degree of conceptual overlap between the
source and target measures
Missing data 9 State how much data were missing and how missing data were handled in the
sample(s) used for the analyses





11 Describe how predicted scores or utilities are estimated for each model
specification
Validation methods 12 Describe and justify the methods used to validate the mapping algorithm
Measures of model
performance
13 State and justify the measure(s) of model performance that determine the choice of
the preferred model(s) and describe how these measures were estimated and
applied
Results
Final sample size(s) 14 State the size of the estimation sample and any validation sample(s) used in the
analyses (including both number of individuals and number of observations)
Descriptive
information
15 Describe the characteristics of individuals in the sample(s) (or refer back to
previous publications giving such information). Provide summary scores for
source and target measures, and summarise results of analyses used to assess
overlap between the source and target measures
Model selection 16 State which model(s) is(are) preferred and justify why this(these)
model(s) was(were) chosen
Model coefficients 17 Provide all model coefficients and standard errors for the selected model(s).
Provide clear guidance on how a user can calculate utility scores based on the
outputs of the selected model(s)
Uncertainty 18 Report information that enables users to estimate standard errors around mean
utility predictions and individual-level variability
Model performance
and face validity
19 Present results of model performance, such as measures of prediction accuracy and
fit statistics for the selected model(s) in a table or in the text. Provide an
assessment of face validity of the selected model(s)
278 Qual Life Res (2016) 25:275–281
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The MAPS explanation and elaboration paper
In addition to the MAPS reporting statement, we have
produced a supporting explanation and elaboration paper
[16] modelled on those developed for other reporting
guidelines [9–14]. The reporting items contained within the
MAPS statement are best understood by referring to the
information contained within this accompanying docu-
ment. The explanation and elaboration paper provides
exemplars of good reporting practice identified from the
published literature for each reporting item. In addition, it
provides a detailed explanation to accompany each rec-
ommendation, supported by a rationale and relevant evi-
dence where available. The development of the explanation
and elaboration paper was completed following several
iterations produced by members of the working group, after
which the examples and explanations were shared with the
Delphi panellists for final revisions to improve readability
and their approval. The explanation and elaboration paper
also summarises the characteristics of the Delphi panellists
and provides detailed statistics for item ratings at each
Delphi round.
Discussion
Over recent years, there has been a rapid increase in the
publication of studies that use mapping techniques to pre-
dict health utility values. One recent review article identi-
fied ninety studies published up to the year 2013 reporting
121 mapping algorithms between clinical or health-related
quality of life measures and the EQ-5D [2]. That review
article excluded mapping algorithms targeted at other
generic preference-based outcome measures that can gen-
erate health utilities, such as the SF-6D [17] and the Health
Utilities Index (HUI) [18], which have been the target of
numerous other mapping algorithms (e.g. [1, 19–24] ).
Moreover, the popularity of the mapping approach for
estimating health utilities is unlikely to wane given the
numerous contexts within health economic evaluation
where primary data collection is challenging. However,
mapping introduces additional uncertainty, and collection
of primary data with the preferred utility instrument is
preferable.
The MAPS reporting statement was developed to pro-
vide recommendations, in the form of a checklist of
essential items, which authors should consider when
reporting mapping studies. Guidance for the reporting of
mapping studies was not previously available in the liter-
ature. The overall aim of MAPS is to promote clarity,
transparency and completeness of reporting of mapping
studies. It is not intended to act as a methodological guide,
nor as a tool for assessing the quality of study methodol-
ogy. Rather, it aims to avoid misleading conclusions being
drawn by readers, and ultimately policy makers, as a result
of suboptimal reporting. In keeping with other recent health
research reporting guidelines, we have also produced an
accompanying explanation and elaboration paper [16] to
facilitate a deeper understanding of the 23 items contained
within the MAPS reporting statement. That paper should
hopefully act as a pedagogical framework for researchers
reporting mapping studies.
The development of the MAPS reporting statement, and
its explanation and elaboration document, was framed by
recently published guidance for health research reporting
guidelines [5]. The Delphi panel was composed of a mul-
tidisciplinary, multinational team of content experts and
journal editors. The panel members included people
experienced in conducting mapping studies; of the 84









20 Report details of previously published studies developing mapping algorithms
between the same source and target measures and describe differences between
the algorithms, in terms of model performance, predictions and coefficients, if
applicable
Study limitations 21 Outline the potential limitations of the mapping algorithm.
Scope of
applications





23 Describe the source(s) of funding and non-monetary support for the study, and the
role of the funder(s) in its design, conduct and report. Report any conflicts of
interest surrounding the roles of authors and funders
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recent review of EQ-5D mapping studies [2], 31 (36.9 %)
were included as panellists. We have no evidence to
believe that a larger panel would have altered the final set
of recommendations. The Delphi methodologies that we
applied included analytical approaches only recently
adopted by developers of health reporting guidelines [15].
We are unable to assess whether a strict adherence to the
MAPS checklist will increase the word counts of mapping
reports. It is our view that the increasing use of online
appendices by journals should permit comprehensive
reporting even in the context of strict word limits for the
main body of reports.
Evidence for other health research reporting guidelines
suggests that reporting quality improved after the intro-
duction of reporting checklists [25–27], although there is
currently no empirical evidence that adoption of MAPS
will improve the quality of reporting of mapping research.
Future research planned by the MAPS working group will
include a before and after evaluation of the benefits (and
indeed possible adverse effects) of the introduction of the
MAPS reporting statement. It will also be necessary to
update the MAPS reporting statement in the future to
address conceptual, methodological and practical advances
in the field. Potential methodological advances that might
be reflected in an update might include shifts towards more
complex model specifications, better methods for dealing
with uncertainty and guidance on appropriate use of mea-
sures of prediction accuracy, such as mean absolute error
(MAE) and mean square error (MSE). The MAPS working
group plans to assess the need for an update of the
reporting checklist in 5 years’ time.
In conclusion, this paper summarises a new reporting
statement developed for studies that map onto generic
preference-based outcome measures. We encourage health
economic and quality of life journals to endorse MAPS,
promote its use in peer review and update their editorial
requirements and ‘Instructions to Authors’ accordingly.
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